HOME > About LGLS > Corporate Information > History

History

2002.6 ~ 2005 2000~2002.6 1990~1999 1980~1989 1947~1979
1990~1999
Apr.1990 Anjin Pharmaceuticals renamed Lucky Pharmaceuticals.
Dec.1990 Interferon-gamma product sold as Intermax-gamma.
Jan.1991 World first 4th-generation cephalosporin antibiotic completed; technology exported to Glaxo (now GSK) of the UK.
Feb.1991 Korean government GMP designation granted to pharmaceutical plant.
Jun.1991 Interferon-gamma given IR52 Chang Young-sil Award.
Nov.1991 Lucky Pharmaceuticals merged with Lucky Ltd.
Jan.1992 US$4M worth of Intermax-gamma exported to Thailand.
Feb.1992 Korea first in-vitro diagnostics for hepatitis (LUCKY-HCD™) commercialized.
Sept.1992 Intermax-alpha, Intermax-gamma and hepatitis B vaccine exported to Egypt.
Jan.1993 Korea first human growth hormone (EUTROPIN™) put on market.
Apr.1993 Procymidone pesticide commercialized for horticultural use.
Aug.1993 EUTROPIN™ human growth hormone given IR52 Chang Young-sil Award.
Aug.1993 EUVAX B™ hepatitis B vaccine exported to Singapore.
Jan.1994 Agrochemical Business Division launched.
Jan.1994 Procymidone pesticide given IR52 Chang Young-sil Award.
Jan.1994 In-vitro diagnostics for hepatitis C (LG-HCD) completed.
Sept.1994 BOOSTIN recombinant BST commercialized.
Oct.1994 Genetically engineered products (EUTROPIN™, Intermax-alpha, EUVAX B™) introduced to S. American market; first phase of LG Chemical Research Park completed.
Jan.1995 Company renamed LG Chemical; new CI launched.
Feb.1995 Contract signed for agrochemical production joint venture in China.
Mar.1995 Leukocyte production stimulant (LEUCOGEN™) commercialized.
Apr.1995 First phase of Iksan pharmaceutical plant competed.
Jun.1995 BOOSTIN rBST exported to Egypt.
Jul.1995 BOOSTIN rBST given IR52 Chang Young-sil Award.
Aug.1995 Iksan plant granted KGMP designation for 9 major pharmaceutical products.
Nov.1995 Production technology for hypertension treatment received from Nippon Chemipha.
Mar.1996 R&D operation reorganized into Biotech I and Biotech II.
Jun.1996 Aggregate exports of rBST topped US$5M.
Sept.1996 Leukocyte production stimulant (LEUCOGEN™) given IR52 Chang Young-sil Award.
Oct.1996 Second phase of LG Chemical Research Park completed.
Nov.1996 Agreement for joint research on cardio-circulatory disease signed with TBC of the US.
Jan.1997 Agrochemical R&D Center opened (independent of Specialty Chemical R&D Center).
New-formula herbicide (PYANCOR commercialized.
Mar.1997 LGBMI established in US as bioengineering research facility.
Apr.1997 DAMA, Korea first cephalosporin antibiotic intermediate, commercialized.
May1997 Quinolone antibiotic technology exported to Smith-Kline Beecham Pharmaceuticals of the UK.
Jun.1997 EUVAX B™ hepatitis B vaccine exported for 3rd world immunization program.
Jul.1997 DAMA cephalosporin antibiotic intermediate given IR52 Chang Young-sil Award; production technology for oral anticoagulant medication exported to Warner Lambert of the US.
Sept.1997 Strategic marketing alliance for 6 genetically engineered drugs signed with Merck of Germany.
Dec.1997 Herbicide (PYANCOR given IR52 Chang Young-sil Award of the Year (Presidential Prize).
Mar.1998 Sodium hyaluronate for ophthalmic surgery (HYAL 2000® Injection) commercialized.
Apr.1998 Company designated fficial chemical substance toxicity testing institution.
May1998 PYANCOR herbicide and hyaluronic acid (hyaluronsan) arthritis treatment given KT Mark and awarded LG R&D Prize.
Jun.1998 LG Chemical Research Park Quniolone Team won Prime Minister Prize at Patent Technology Awards; hyaluronan arthritis treatment commercialized; BST marketing agreement concluded with Shering-Plough of the US; ACCENT™ veterinarian-use antibiotic commercialized.
Sept.1998 Quinolone antibiotic completed Phase II Clinical Trial overseas.
Oct.1998 Choson ilbo selects EUTROPIN™ as one of ROK 50 top scientific achievements.
Nov.1998 EUVECTIN™ parasiticide for cattle commercialized.
Dec.1998 Deltamethrin agrochemical base chemical given IR52 Chang Young-sil Award.
Feb.1999 Agreement for joint research of antivirus compounds signed with Smith-Beecham of the UK.
Mar.1999 Development of GUARDIAN an environmentally benign fungicide, completed.
Apr.1999 ESPOGEN™ anemia treatment commercialized.
Oct.1999 GUARDIAN fungicide given Central Patented Technology Prize; strategic agreement for overseas marketing of PYANCOR herbicide signed with Rohm & Haas Company; LG LARVANIL larvacide for animal feed commercialized.
Nov.1999 Permethrin insecticide registered at US Environmental Protection Agency.
Dec.1999 Quinolone antibiotic completed Phase III Clinical Trial overseas; application submitted for FDA approval.